This document provides an overview of drugs, medical devices, clinical trials, healthcare IT, and regulations. It discusses the types and administration of drugs. It describes medical devices and their types. It explains the objectives, design, and types of clinical trials. It discusses the role of IT in clinical trials and healthcare, including clinical trial management systems and electronic health records. It provides information on the healthcare and clinical trial management systems market. Finally, it lists some key regulating bodies and regulations.
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Intro to informatics pharmacist by Linus LayLinus Lay
Presented by Linus Lay, Pharm.D. Candidate from the University of Rhode Island Class of 2022.
This presentation was in-service to RxInsider, a B2B multimedia publishing and technology company for the "business of pharmacy." Pharmacy Informatics is a rising field in the specialties of pharmacy. This presentation provides a brief background on the responsibilities of an informatics pharmacist, short history of the specialty curriculum, and the current education for the field of informatics for student pharmacists.
View MyCred Portfolio: https://mycred.com/p/2929377185
View Youtube Video: https://youtu.be/WTi2ldztl2I
The competitiveness of drug development has been the impetus for new and accelerated regulatory pathways. While the growing patient-centric healthcare market coupled with a vested interest in safety information from a range of governmental and regulatory stakeholders has driven pharmacovigilance to reach a new paradigm in drug development. The consequence of which has led to tighter post-marketing surveillance systems on the global scale and a rapidly expanding volume of reported safety events impelling the industry to adopt new strategies to managing pharmacovigilance throughout the product lifecycle. In view of all these changes, it is timely to provide an overview on the concept of Pharmacovigilance, and here i3 Consult has published in this Slide Share, some key topics on Pharmacovigilance such as Signal Detection, Detection Management, Risk Management and Risk Reduction Strategies. At i3 Consult, our core team of experts & our 200,000+ network bring innovative ideas, cost effective solutions and game changing services to healthcare, pharma & life science, for more details, visit www.i3consult.com
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Intro to informatics pharmacist by Linus LayLinus Lay
Presented by Linus Lay, Pharm.D. Candidate from the University of Rhode Island Class of 2022.
This presentation was in-service to RxInsider, a B2B multimedia publishing and technology company for the "business of pharmacy." Pharmacy Informatics is a rising field in the specialties of pharmacy. This presentation provides a brief background on the responsibilities of an informatics pharmacist, short history of the specialty curriculum, and the current education for the field of informatics for student pharmacists.
View MyCred Portfolio: https://mycred.com/p/2929377185
View Youtube Video: https://youtu.be/WTi2ldztl2I
The competitiveness of drug development has been the impetus for new and accelerated regulatory pathways. While the growing patient-centric healthcare market coupled with a vested interest in safety information from a range of governmental and regulatory stakeholders has driven pharmacovigilance to reach a new paradigm in drug development. The consequence of which has led to tighter post-marketing surveillance systems on the global scale and a rapidly expanding volume of reported safety events impelling the industry to adopt new strategies to managing pharmacovigilance throughout the product lifecycle. In view of all these changes, it is timely to provide an overview on the concept of Pharmacovigilance, and here i3 Consult has published in this Slide Share, some key topics on Pharmacovigilance such as Signal Detection, Detection Management, Risk Management and Risk Reduction Strategies. At i3 Consult, our core team of experts & our 200,000+ network bring innovative ideas, cost effective solutions and game changing services to healthcare, pharma & life science, for more details, visit www.i3consult.com
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
Introduction to MedDRA Coding in Drug Safety & Pharmacovigilance Process for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance Training in Oracle Argus Safety DatabaseGratisol Labs
Pharmacovigilance training is essential for pharmaceutical and healthcare organizations to ensure your operations comply with the latest regulatory guidelines, laws and standards. At Gratisol Labs, we provide industry-leading pharmacovigilance training courses with hands on experience on safety databases & medical coding that cover the basics of Pharmacovigilance till advanced drug safety topics, the regulatory requirements of pharmacovigilance, signal detection, and pharmacovigilance audits are covered in the complete Gratisol Labs Pharmacovigilance Training Programme.
The presentation provides information about Buddhist Pilgrimage sites situated in India and Nepal. Destinations include religious places like Lumbini, Bodh Gaya, Sarnath, Kushinagar, Dharamshala with others.
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
Introduction to MedDRA Coding in Drug Safety & Pharmacovigilance Process for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance Training in Oracle Argus Safety DatabaseGratisol Labs
Pharmacovigilance training is essential for pharmaceutical and healthcare organizations to ensure your operations comply with the latest regulatory guidelines, laws and standards. At Gratisol Labs, we provide industry-leading pharmacovigilance training courses with hands on experience on safety databases & medical coding that cover the basics of Pharmacovigilance till advanced drug safety topics, the regulatory requirements of pharmacovigilance, signal detection, and pharmacovigilance audits are covered in the complete Gratisol Labs Pharmacovigilance Training Programme.
The presentation provides information about Buddhist Pilgrimage sites situated in India and Nepal. Destinations include religious places like Lumbini, Bodh Gaya, Sarnath, Kushinagar, Dharamshala with others.
Land of Buddha: 20 Holy Buddhist Places in IndiaTrodly
Practicing Buddhism is most common in Himalayan regions like Ladakh, Sikkim and Arunachal Pradesh and there are many sites of religious importance to Buddhists in India. Here are some of the places of significance and Buddhist holy sites in India:
Overview of Health Informatics: survey of fundamentals of health information technology, Identify the forces behind health informatics, educational and career opportunities in health informatics.
The convergence of separate health systems has led to
a great increase in data, which some organisations are
struggling to get to grips with. Harnessing analytic tools
and sharing knowledge is the best way forward
AI in medicine revolutionizes healthcare through precision diagnostics, personalized treatments, and predictive analytics, enhancing patient outcomes, bridging gaps in access, and fostering innovation and collaboration for a healthier future.
1. Introduction to Pharma and Healthcare IT- Drug, Device, Systems- The era of Human technology
Dr. Anirban Mukherjee. Phd
2. Agenda in Sequential Order
Our Body – Back to school
Drug, Medical Device, Clinical Trial
Clinical Trial Design and Types
IT in Clinical Trial
Healthcare
It in Healthcare
Regulation
Ideas
2
3. A substance recognized by an official pharmacopoeia or formulary. A substance intended for
use in the diagnosis, cure, mitigation, treatment, or prevention of disease. A substance (other
than food) intended to affect the structure or any function of the body.
Drugs can be of different types
Medication – Pharmaceutical
Spiritual/religious – Etheogenic
Self-improvement – Nootropic
Recreational
Administration:
Bolus
Inhalation
Injection
Insufflation
Oral
Suppository
Sublingually
Topically
Drug
3
6. • Clinical trials are research studies that explore whether a medical strategy, treatment, or
device is safe and effective for humans. These studies also may show which medical
approaches work best for certain illnesses or groups of people
• The study can be biomedical or behavioral designed to answer specific questions about
interventions (novel vaccines, drugs, treatments, functional foods, dietary supplements,
devices or new ways of using known interventions), generating safety and efficacy data.
•
• Clinical trials can vary in size, and can involve a single research entity in one country or
multiple entities in multiple countries.
• A full series of trials may cost hundreds of millions of dollars. The sponsor could be a
governmental organization or pharmaceutical, biotechnology or medical device company.
• When the required support exceeds the sponsor's capacity, the trial may be managed by
an outsourced partner, such as a contract research organization or an academic clinical trials
unit.
Clinical Trials
6
11. Customizable software systems to manage large amount of data involving the clinical trial
operation
The clinical trial includes but not exclusive of following data:
Scientific data
Administrative data
Regulatory data
Demographic data
Marketing data
Trial configuration data
……………………..
Software to aid in planning, preparation, performance, and reporting (AE data), keeping up-to-
date contact information for participants and tracking deadlines and milestones such as those
for regulatory approval or the issue of progress reports of Clinical Trial
Clinical Trial also need to be connected to a business intelligence system, which may acts as
a digital dashboard for trial managers
Need of IT in Clinical Trial
11
12. CTMS
CDMS
CDARS
CDS
eCRF
eCTD
Medical Device Software
Clinical Trial Measure Software
Telemedicine
Could medicine
Clinical trial and IT
12
17. Test time ~2-3 minutes
349 straight variable out puts
140 derived statistical variable
Typical –STM-Measure Output
17
18. The worldwide revenue of the pharmaceutical market in 2001 was around 390.2 billion U.S.
dollars. Ten years later, this figure stood at almost one trillion U.S. dollars. And it is ever
growing.
Global Clinical Trial Management Systems’ Market valuation is predicted to be $1300.4 Million
by 2016.
The global CTMS market is estimated to grow at a CAGR of 14.53% during period (2011-2016).
North America is leading the global CTMS market with around 62% share in 2010, as majority of
the global clinical trials are conducted in North America, especially in the U.S. (around 58.5%
share).
The second largest market is Europe, while growth in the Asia-Pacific region is also expected to
take greater curves in the near future.
Major players in the Clinical Trial Management Systems Market include Oracle Corporation
(U.S.), Perceptive Informatics (a subsidiary of Parexel International Corporation) (U.S.),
Medidata Solutions (U.S.), eResearch Technology Inc. (U.S.), and BioClinica Inc. (U.S.).
Clinical Trial Management Systems (CTMS) Market: Global Trends, Opportunities, Challenge and Forecasts (2011 - 2016)
The CTMS Market
18
19. Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness,
injury, and other physical and mental impairments in human beings.
Health care is delivered by healthcare practitioners, associates and related service providers.
Healthcare services can be extended to primary care, secondary care, and tertiary care, as well
as in public health.
Total health care spending in the United States is expected to reach $4.8 trillion in 2021, up
from $2.6 trillion in 2010 and $75 billion in 1970. To put it in context, this means that health
care spending will account for nearly 20 percent of gross domestic product (GDP), or one-fifth
of the U.S. economy, by 2021.
HealthCare
19
20. Health information technology (HIT) provides the umbrella framework to describe
the comprehensive management of health information across computerized
systems and its secure exchange between consumers, providers, government and
quality entities, and insurers.
Broad and consistent utilization of HIT will:
Improve health care quality or effectiveness;
Increase health care productivity or efficiency;
Prevent medical errors and increase health care accuracy and procedural correctness;
Reduce health care costs;
Increase administrative efficiencies and healthcare work processes;
Decrease paperwork and unproductive or idle work time;
Extend real-time communications of health informatics among health care professionals; and
Expand access to affordable care
Examples of health IT include the following:
Clinical decision support.
Computerized disease registries.
Computerized provider order entry.
Consumer health IT applications.
HealthCare IT
20
21. EHR
EMR
HMS
HIS
PMS
PHRs
E-prescribing
Telemedicine
Telehealth
HealthCare IT
21
24. EHR
24
EHR Should Contain:
Health information and data,
Result management,
Order entry/order management,
Decision support,
Electronic communication and connectivity,
Patient support,
Administrative processes,
Reporting and population health.
EHR is utilized for:
Patient Care Delivery
Patient Care Management
Patient Care Support Processes
Financial and Other Administrative Processes
Patient Self-Management
Education
Regulation
Research
Public Health and Homeland Security
Policy Support
33. • European Federation of Pharmaceutical Industries and Associations (EFPIA)
• Ministry of Health, Labor and Welfare, Japan (MHLW)
• Japan Pharmaceutical Manufacturers Association (JPMA)
• US Food and Drug Administration (FDA)
• Therapeutic Products Directorate (TPD)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• --------------------------- (many more)
Controlling bodies
33
34. • 21 CFR (Part11, Part210 and 211, Part820 or Quality System Regulation, Part 807, Part 814 etc.)
• 520(k)/PMA
• GDMP, GMP, CAPA
• The Hazard Analysis and Critical Control Points (HCCP)
• ASTM D1585, ASTM F2097, EN 868, ISO 11607, CE Marking
• HIPAA , ARRA, HITECH Act, EDI transaction and code sets
• HCP Aggregate Spend Reporting, PPACA, Physician’s Sunshine Legislation, US State and Federal
regulations.
• CDISC (SDTM and ODM)
• PhRMA regulations
• CRF 42
• ISO 9001, ISO 14971, ISO 13485,
• IEC 62304
Regulations
34
Editor's Notes
As we go about our daily routine in every moment of our lives
Most of us do not realize, how amazing our body is, how extraordinary is each moment of our existence in this widely confusing universe, how mesmerizing is life itself.
Today we would discuss about life and a trial of human inquisitiveness to unfold mysteries of it.
Simple Devices
Tongue depressors and bedpans
Complex Devices
Programmable pacemakers
Laser surgical devices
Medical Device Classification – Class I, II, and III base on risk
Stages of Clin. Trial.:
Synthesis and Extraction
Biological Screening and Pharmacological Testing
Pharmaceutical Dosage Formulation and Stability Testing
Toxicology and Safety Testing
Regulatory Review: Investigational New Drug (IND) Application
Phase I Clinical Evaluation
Phase II Clinical Evaluation
Phase III Clinical Evaluation
Process Development for Manufacturing and Quality Control
Bioavailability Studies
Regulatory Review: New Drug Application (NDA)
Post approval Research (referred to as phase IV studies in the United States)
Drug Price
Electronic health records (EHRs). EHRs allow doctors to better keep track of your health information and may enable them to see it when you have a problem even if their office is closed. EHRs also make it easier for your doctor to share information with specialists, so that specialists who need your information have it available when it’s needed.
Personal health records (PHRs). A PHR is a lot like an EHR, except that you control what kind of information goes into it. You can use a PHR to keep track of information from your doctor visits, but the PHR can also reflect your life outside the doctor’s office and your health priorities, such as tracking what you eat, how much you exercise, and your blood pressure. Sometimes, your PHR can link with your doctor’s EHR.
Electronic prescribing (E-prescribing). A paper prescription can get lost or misread. E-prescribing allows your doctor to communicate directly with your pharmacy. This means you can go to the pharmacy to pick up medicine without having to bring the paper prescription.